You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

 

Online download statistics by month:

Online download statistics by month: December 2019 to June 2025

AbstractFullPdf
Dec 2019110
Jan 2020660
Feb 202011114
Mar 202017173
Apr 202014140
May 202029292
Jun 202024240
Jul 202014144
Aug 202020208
Sep 2020313111
Oct 2020323210
Nov 2020222210
Dec 202013135
Jan 202119198
Feb 2021993
Mar 2021242414
Apr 2021232318
May 202118187
Jun 202123237
Jul 2021191910
Aug 2021131220
Sep 2021272723
Oct 2021171730
Nov 2021212122
Dec 202117179
Jan 202216175
Feb 2022242611
Mar 2022353821
Apr 2022404213
May 2022464714
Jun 2022373811
Jul 202224256
Aug 202220203
Sep 2022161611
Oct 202214143
Nov 2022333424
Dec 2022292913
Jan 202325256
Feb 202325269
Mar 2023757613
Apr 202320217
May 2023141415
Jun 202316162
Jul 2023313117
Aug 202323238
Sep 202322227
Oct 202328287
Nov 2023161610
Dec 202320205
Jan 2024363612
Feb 202423237
Mar 2024666621
Apr 2024252613
May 202428288
Jun 2024292914
Jul 2024555513
Aug 202417178
Sep 2024232312
Oct 2024323222
Nov 202434357
Dec 202446469
Jan 202541449
Feb 2025292914
Mar 2025606018
Apr 2025505011
May 2025383825
Jun 202538389
Total17831802701